(2)
FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer s investigational drug PF-06946860
Unintentional weight loss (cachexia) is a highly prevalent complication of cancer, affecting more than half of all cancer patients worldwide, potentially leading to significant functional impairment and increased risk of death
Successful cachexia treatment can potentially contribute to improved cancer treatment worldwide
Basel, 8 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to their Elecsys GDF-15 assay as a companion diagnostic (CDx) in cancer treatment. This in vitro diagnostic immunoassay is intended for measurement of Growth Differentiation Factor-15 (GDF-15) in cachectic patients 18 years of age and older with solid tumours for treatment with Pfizer Inc. s (NYSE: PFE) investigational d
F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020
Group sales increase 1%
1 at constant exchange rates (CER); 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies
Pharmaceuticals Division sales decline 2%; continued strong sales growth of newly launched medicines (+32%
2, including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla) largely offsets the impact of competition from biosimilars (CHF -5.1 billion at CER
3), but not the additional COVID-19-related impact from missed medical appointments
Diagnostics Division sales grow 14% for the full year (+28% in the fourth quarter) due to COVID-19 diagnostics; more than offsetting a decline in routine testing due to COVID-19
F. Hoffmann-La Roche Ltd: Roche renews partnership with Sysmex to deliver haematology testing solutions
This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally
The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience
Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests
1
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement (GBP) with Sysmex. Under this new framework, the parties renewed their commitment to the long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex haematology products, including instruments and reagents.
Roche renews partnership with Sysmex to deliver haematology testing solutions
Nachrichtenquelle: globenewswire | 25.01.2021, 07:03 | 171
This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally
The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience
Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests
1 Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement (GBP) with Sysmex. Under this new framework, the parties renewed their commitment to the long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex haematology products, includ